Tag Archive for: Curve Therapeutics

Research published in Journal of the American Chemical Society highlights potential of HIF Inhibition as a therapeutic approach for cancers

Research led by Curve CSO Professor Ali Tavassoli’s laboratory at University of Southampton Landmark paper on dual HIF-1 and HIF-2 inhibitor that works by inhibiting the interaction of both HIF-1α and HIF-2α with HIF-1β   Southampton, UK, 26 March 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular […]

Curve Therapeutics raises £40.5 million to turbocharge discovery platform and advance breakthrough pipeline

Series A financing led by Pfizer Ventures with new investors Columbus Venture Partners and British Patient Capital which join founding investor Advent Life Sciences and seed investor Epidarex Capital Goal to advance proprietary discovery platform and progress pipeline of assets addressing challenging cancer targets into the clinic Southampton, UK, 27 February 2023 – Curve Therapeutics […]

Curve Therapeutics Expands Leadership Team and Scientific Advisory Board

Dr Monika Ermann appointed Vice President Drug Discovery to advance Curve’s therapeutic programmes directed at challenging cancer targets Prof. Julian Downward (Francis Crick Institute) and Prof. Steven Benkovic (Penn State University) join the Scientific Advisory Board Relocation to bespoke laboratories and offices at Southampton Science Park Read more…